Compare ACRS & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | LXFR |
|---|---|---|
| Founded | 2012 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 376.0M |
| IPO Year | 2015 | 2012 |
| Metric | ACRS | LXFR |
|---|---|---|
| Price | $2.65 | $13.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 110.1K |
| Earning Date | 11-06-2025 | 02-24-2026 |
| Dividend Yield | N/A | ★ 3.76% |
| EPS Growth | N/A | ★ 55.43 |
| EPS | N/A | ★ 0.53 |
| Revenue | $15,742,000.00 | ★ $397,300,000.00 |
| Revenue This Year | N/A | $0.62 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.23 |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $1.05 | $9.41 |
| 52 Week High | $3.48 | $14.96 |
| Indicator | ACRS | LXFR |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 62.93 |
| Support Level | $2.88 | $13.49 |
| Resistance Level | $3.04 | $14.08 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 20.12 | 76.19 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.